NewcelX Expands Intellectual Property Footprint with Publication of DOXA Patent Application in China
PRNewswire (Thu, 11-Dec 7:00 AM ET)
PRNewswire (Mon, 17-Nov 7:00 AM ET)
PRNewswire (Thu, 6-Nov 7:00 AM ET)
NewcelX CEO Issues Letter to Shareholders
PRNewswire (Tue, 4-Nov 7:00 AM ET)
Market Chameleon (Mon, 3-Nov 3:50 AM ET)
PRNewswire (Mon, 3-Nov 8:26 AM ET)
NewcelX Ltd is a biotechnology company developing transformative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The company's integrated platform combines advanced stem-cell technologies and neuroscience expertise to deliver scalable, regenerative treatments targeting conditions such as Amyotrophic Lateral Sclerosis (ALS) and Type 1 Diabetes. It has research and development operations in Ness Ziona, Israel.
Newcelx Ltd. - trades on the NASDAQ stock market under the symbol NCEL.
As of December 24, 2025, NCEL stock price climbed to $2.63 with 18,780 million shares trading.
NCEL has a market cap of $11.99 million. This is considered a Sub-Micro Cap stock.
NCEL support price is $2.27 and resistance is $2.79 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NCEL shares will trade within this expected range on the day.